Andrew Hill

12.1k total citations · 2 hit papers
195 papers, 6.7k citations indexed

About

Andrew Hill is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Andrew Hill has authored 195 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 154 papers in Infectious Diseases, 102 papers in Virology and 44 papers in Epidemiology. Recurrent topics in Andrew Hill's work include HIV/AIDS drug development and treatment (129 papers), HIV Research and Treatment (102 papers) and HIV/AIDS Research and Interventions (98 papers). Andrew Hill is often cited by papers focused on HIV/AIDS drug development and treatment (129 papers), HIV Research and Treatment (102 papers) and HIV/AIDS Research and Interventions (98 papers). Andrew Hill collaborates with scholars based in United Kingdom, United States and South Africa. Andrew Hill's co-authors include Bryony Simmons, Anton Pozniak, Graham Cooke, Katherine Heath, Victoria Pilkington, Jacob Levi, Dzintars Gotham, Toby Pepperrell, François Venter and Michael S. Simberkoff and has published in prestigious journals such as Science, New England Journal of Medicine and The Lancet.

In The Last Decade

Andrew Hill

189 papers receiving 6.5k citations

Hit Papers

Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts an... 1996 2026 2006 2016 1996 2019 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDS
    1996 595 citations Andrew Hill et al. New England Journal of Medicine profile →
  2. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV
    2019 442 citations François Venter, Michelle Moorhouse et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew Hill United Kingdom 43 4.8k 3.1k 1.8k 1.2k 993 195 6.7k
Veronica Miller United States 43 4.8k 1.0× 4.1k 1.3× 2.6k 1.5× 659 0.5× 855 0.9× 128 7.5k
Andrew Zolopa United States 43 5.6k 1.2× 3.6k 1.2× 1.9k 1.1× 1.3k 1.0× 310 0.3× 107 6.9k
Gilles Peytavin France 40 4.8k 1.0× 3.7k 1.2× 1.2k 0.7× 872 0.7× 618 0.6× 267 6.3k
Judith Feinberg United States 43 5.0k 1.0× 3.3k 1.1× 3.2k 1.8× 1.2k 0.9× 423 0.4× 169 8.0k
Alexandra Calmy Switzerland 53 6.5k 1.3× 3.8k 1.2× 3.2k 1.8× 3.3k 2.7× 801 0.8× 305 10.1k
Diane Aschman United States 7 5.7k 1.2× 3.8k 1.2× 2.9k 1.6× 2.0k 1.6× 445 0.4× 12 7.8k
Judith A. Aberg United States 51 5.9k 1.2× 2.5k 0.8× 3.0k 1.7× 2.9k 2.3× 543 0.5× 200 9.2k
Chloe Orkin United Kingdom 39 3.8k 0.8× 2.7k 0.9× 1.8k 1.0× 1.8k 1.5× 885 0.9× 168 6.0k
Pedro Cahn Argentina 46 7.4k 1.5× 5.2k 1.7× 2.6k 1.4× 2.0k 1.7× 626 0.6× 217 9.3k
Patrick Yéni France 31 6.8k 1.4× 5.3k 1.7× 2.1k 1.2× 1.7k 1.3× 519 0.5× 89 8.5k

Countries citing papers authored by Andrew Hill

Since Specialization
Citations

This map shows the geographic impact of Andrew Hill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Hill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Hill more than expected).

Fields of papers citing papers by Andrew Hill

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Hill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Hill. The network helps show where Andrew Hill may publish in the future.

Co-authorship network of co-authors of Andrew Hill

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Hill. A scholar is included among the top collaborators of Andrew Hill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Hill. Andrew Hill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hill, Andrew, Mark J. Siedner, Cassandra Fairhead, & François Venter. (2025). The Need for Lenacapavir Compulsory Licences in Ending the HIV Epidemic. Clinical Infectious Diseases. 81(3). 547–554. 3 indexed citations
3.
Manne‐Goehler, Jennifer, June Fabian, Simiso Sokhela, et al.. (2024). Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa. Journal of the International AIDS Society. 27(7). e26268–e26268. 1 indexed citations
4.
Siedner, Mark J., et al.. (2024). Virologic Failure and Emergent Integrase Strand Transfer Inhibitor Drug Resistance With Long-Acting Cabotegravir for HIV Treatment: A Meta-analysis. Clinical Infectious Diseases. 81(2). 274–285. 10 indexed citations
5.
Levi, Jacob, Junzheng Wang, François Venter, & Andrew Hill. (2023). Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment. Obesity. 31(5). 1270–1279. 38 indexed citations
6.
Chandiwana, Nomathemba, Mark J. Siedner, Vincent C. Marconi, et al.. (2023). Weight Gain After HIV Therapy Initiation: Pathophysiology and Implications. The Journal of Clinical Endocrinology & Metabolism. 109(2). e478–e487. 23 indexed citations
7.
8.
Hill, Andrew, et al.. (2022). Evaluation of publication bias for 12 clinical trials of molnupiravir to treat SARS-CoV-2 infection in 13 694 patients with meta-analysis. Journal of Antimicrobial Chemotherapy. 78(3). 613–619. 8 indexed citations
9.
Hill, Andrew, et al.. (2022). Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud. Open Forum Infectious Diseases. 9(2). ofab645–ofab645. 31 indexed citations
10.
Hill, Andrew, et al.. (2022). Ivermectin for the prevention of COVID-19: addressing potential bias and medical fraud. Journal of Antimicrobial Chemotherapy. 77(5). 1413–1416. 10 indexed citations
11.
Sokhela, Simiso, Andrew Hill, Bryony Simmons, et al.. (2022). Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection. Journal of Antimicrobial Chemotherapy. 77(10). 2706–2712. 6 indexed citations
12.
Wang, Junzheng, et al.. (2021). Minimum Manufacturing Costs, National Prices, and Estimated Global Availability of New Repurposed Therapies for Coronavirus Disease 2019. Open Forum Infectious Diseases. 9(1). ofab581–ofab581. 17 indexed citations
13.
Siedner, Mark J., Michelle Moorhouse, Bryony Simmons, et al.. (2020). Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase. Nature Communications. 11(1). 5922–5922. 59 indexed citations
14.
Venter, François, Michelle Moorhouse, Simiso Sokhela, et al.. (2019). Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. New England Journal of Medicine. 381(9). 803–815. 442 indexed citations breakdown →
15.
Mofenson, Lynne, Anton Pozniak, Elliot Raizes, et al.. (2019). Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects. Journal of the International AIDS Society. 22(7). e25352–e25352. 30 indexed citations
16.
Arribas, José Ramón, PM Girard, Nicholas I. Paton, et al.. (2015). Efficacy of protease inhibitor monotherapy vs . triple therapy: meta‐analysis of data from 2303 patients in 13 randomized trials. HIV Medicine. 17(5). 358–367. 40 indexed citations
17.
Hill, Andrew, Will Sawyer, & Brian Gazzard. (2009). Effects of First-Line Use of Nucleoside Analogues, Efavirenz, and Ritonavir-Boosted Protease Inhibitors on Lipid Levels. HIV Clinical Trials. 10(1). 1–12. 42 indexed citations
18.
19.
Kucey, Daryl S, et al.. (2006). Corrections. Canadian Medical Association Journal. 174(4). 503.3–503. 1 indexed citations
20.
Kucey, Daryl S, et al.. (2006). Corrections. Canadian Medical Association Journal. 174(4). 503.2–503. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Veronica Miller Breakdown of academic impact, for papers by Andrew Zolopa Breakdown of academic impact, for papers by Gilles Peytavin Breakdown of academic impact, for papers by Judith Feinberg Breakdown of academic impact, for papers by Alexandra Calmy Breakdown of academic impact, for papers by Diane Aschman Breakdown of academic impact, for papers by Judith A. Aberg Breakdown of academic impact, for papers by Chloe Orkin Breakdown of academic impact, for papers by Pedro Cahn Breakdown of academic impact, for papers by Patrick Yéni
Rankless by CCL
2026